Payment overview · 2025
General Payments
$13.49
1 reported records · 1 companies
Healthcare provider profile · identity verified
Roger A. Sacry, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CARTHAGE, MO · NPI 1528009529
Verified facts
What the public records show
CMS Open Payments records show Roger A. Sacry, M.D. received $13.49 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.49 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sertraline Hcl | Sertraline Hcl | 498 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 58 |
| Gabapentin | Gabapentin | 445 | 41 |
| Furosemide | Furosemide | 399 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 72 |
| Trazodone Hcl | Trazodone Hcl | 311 | 33 |
| Tramadol Hcl | Tramadol Hcl | 298 | 62 |
| Carvedilol | Carvedilol | 278 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 265 | 31 |
| Losartan Potassium | Losartan Potassium | 243 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 231 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 216 | 48 |
| Omeprazole | Omeprazole | 205 | 28 |
| Donepezil Hcl | Donepezil Hcl | 179 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 20 |
| Metformin Hcl | Metformin Hcl | 149 | 17 |
| Memantine Hcl | Memantine Hcl | 146 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 17 |
| Myrbetriq | Mirabegron | 105 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 104 | suppressed |
| Allopurinol | Allopurinol | 84 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 84 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 45 |
| Potassium Chloride | Potassium Chloride | 79 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | suppressed |
| Valsartan | Valsartan | 77 | 15 |
| Levetiracetam | Levetiracetam | 76 | suppressed |
| Meloxicam | Meloxicam | 70 | 27 |
| Lisinopril | Lisinopril | 69 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 29 |
| Alprazolam | Alprazolam | 68 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 12 |
| Prednisone | Prednisone | 62 | 41 |
| Pregabalin | Pregabalin | 61 | 13 |
| Trulicity | Dulaglutide | 60 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 14 |
| Azithromycin | Azithromycin | 58 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 14 |
| Primidone | Primidone | 55 | suppressed |
| Lorazepam | Lorazepam | 54 | 13 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Jardiance | Empagliflozin | 49 | 12 |
| Mirtazapine | Mirtazapine | 49 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 13 |
| Metformin Hcl Er | Metformin Hcl | 47 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Risperidone | Risperidone | 46 | suppressed |
| Celecoxib | Celecoxib | 42 | 12 |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Glimepiride | Glimepiride | 39 | 12 |
| Eliquis | Apixaban | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 12 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | 11 |
| Ozempic | Semaglutide | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 12 |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.49 · 1 records | ABBVIE INC. | — | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error